Therefore, if the causal role of PATZ1 in the downregulation of tumor PD-L1 expression is confirmed, future work should investigate the possibility that targeting PATZ1 could enhance the efficacy of anti-PD-1/PD-L1 immunotherapy for NSCLC. The gene discussed is PATZ1; the disease is neoplasm.